The meeting occurred as a bipartisan effort is underway in the Senate that two of its sponsors say would lead to $100 billion in savings on prescription-drug spending over a decade.
As medicines—especially those that treat conditions such as anxiety or depression—are becoming more complex, it’s not just the mix of active ingredients that generic drugmakers have to replicate. It’s also the release mechanism.
The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions of biologic drugs.
The struggling grocery chain told employees Friday morning that it plans to discontinue pharmacy operations and has sold customer prescription files to a national drug store chain.
Mylan will start selling a cheaper version of the emergency allergy treatment after absorbing waves of criticism over a growing list price that made it unaffordable for many patients.
Eli Lilly and Co. and its partner cannot stop competitors from selling generic versions of testosterone treatment Axiron, a federal judge in Indianapolis has ruled.
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn’t breach European patents.
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
In a warning shot to investors, the pharmaceutical giant says it expects “2014 to be the most financially challenging year of Lilly’s current period of patent expirations.”
Cymbalta is Eli Lilly and Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world. The drug's patent expired Wednesday.
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
Indianapolis-based WellPoint Inc., the largest U.S. health insurer by enrollment, will favor a copy of the blockbuster cholesterol medication made by Watson Pharmaceuticals Inc., the insurer said.